Krithika Loganath
Overview
Explore the profile of Krithika Loganath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barton A, Craig N, Loganath K, Joshi S, Tsampasian V, Mahendran M, et al.
J Am Coll Cardiol
. 2025 Jan;
85(6):578-591.
PMID: 39772364
Background: Myocardial fibrosis is a key healing response after myocardial infarction driven by activated fibroblasts. Gallium-68-labeled fibroblast activation protein inhibitor ([Ga]-FAPI) is a novel positron-emitting radiotracer that binds activated fibroblasts....
2.
Loganath K, Craig N, Barton A, Joshi S, Anagnostopoulos C, Erba P, et al.
J Nucl Cardiol
. 2024 Dec;
:102106.
PMID: 39672296
Fibrosis is one of the key healing responses to injury, especially within the heart, where it helps to maintain structural integrity following acute insults such as myocardial infarction. However, if...
3.
Whittington B, Tzolos E, Joshi S, Bing R, Andrews J, Loganath K, et al.
Sci Rep
. 2024 Nov;
14(1):26792.
PMID: 39500930
F-GP1 is a novel highly specific radiotracer that binds to activated platelets and thrombus. We aimed to establish the observer repeatability of coronary, carotid and cerebral F-GP1 uptake in patients...
4.
Loganath K, Craig N, Everett R, Bing R, Tsampasian V, Molek P, et al.
JAMA
. 2024 Oct;
333(3):213-221.
PMID: 39466640
Importance: Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis. Objective: To investigate whether early valve intervention reduced...
5.
Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis
Arsenault B, Loganath K, Girard A, Botezatu S, Zheng K, Tzolos E, et al.
JAMA Cardiol
. 2024 Jul;
9(9):835-842.
PMID: 39018080
Importance: There are currently no pharmacological treatments available to slow hemodynamic progression of aortic stenosis. Plasma lipoprotein(a) concentrations predict incident aortic stenosis but its association with hemodynamic progression is controversial....
6.
Dweck M, Loganath K, Bing R, Treibel T, McCann G, Newby D, et al.
Eur Heart J Cardiovasc Imaging
. 2023 Jul;
24(11):1430-1443.
PMID: 37395329
In this EACVI clinical scientific update, we will explore the current use of multi-modality imaging in the diagnosis, risk stratification, and follow-up of patients with aortic stenosis, with a particular...
7.
Effect of race on pressure recovery adjustment for prevention of aortic stenosis grading discordance
Oh J, Shen M, Guzzetti E, Tastet L, Loganath K, Botezatu S, et al.
Heart
. 2023 May;
109(20):1550-1557.
PMID: 37147133
Objective: We sought to evaluate the potential impact of racial difference (Asians vs Caucasians) on the clinical usefulness of pressure recovery (PR) adjustment for preventing discordant aortic stenosis (AS) grading...
8.
Dweck M, Loganath K
JACC Cardiovasc Imaging
. 2022 Oct;
15(10):1768-1770.
PMID: 36202456
No abstract available.
9.
Loganath K, Adamson P, Moss A
Future Cardiol
. 2020 Sep;
17(4):561-571.
PMID: 32960097
Ticagrelor is a potent and orally active P2Y inhibitor. Ticagrelor has been extensively tested in Phase II and Phase III trials in patients with coronary artery disease. The pharmacokinetics and...
10.
Bing R, Loganath K, Adamson P, Newby D, Moss A
Br J Radiol
. 2019 Dec;
93(1113):20190740.
PMID: 31821027
Despite recent advances, cardiovascular disease remains the leading cause of death globally. As such, there is a need to optimise our current diagnostic and risk stratification pathways in order to...